PureTech Health Plc (PRTC)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 7:00 AM EDTNovel antibody demonstrates highly specific and highly potent targeting of immunosuppressive 1 T cells from cancer patients
Enriched in many intractable solid tumors and blood of cancer patients, 1 T cells represent important new target for cancer immunotherapy
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to... More
